Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - The DESolve Nx Trial

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 126 participants.

Also called NCT02086045

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 126 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02086045
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Belgium, Brazil, Denmark, Germany, New Zealand, Poland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02086045. Allocation not applicable; no masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2013-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - The DESolve Nx Trial
Intervention (Device)
DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System
Lead sponsor
Elixir Medical Corporation (class: industry)

Record details

Record id
cardio:ct-nct02086045
Content hash
53c804c2f8157e34054a2f1817a5757f6694bc3abadb571472d81dafc2221b10